Richard Kim, MD
Enriched profileProfessor of Oncology; Service Chief of Medical Gastrointestinal Oncology; Senior Member, Department of Gastrointestinal Oncology · H. Lee Moffitt Cancer Center & Research Institute
Richard Kim is Professor of Oncology; Service Chief of Medical Gastrointestinal Oncology; Senior Member, Department of Gastrointestinal Oncology at H. Lee Moffitt Cancer Center & Research Institute. OpenAlex indexes 348 publications with 6,200 citations (h-index 37); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Richard D. Kim, M D, is Professor of Oncology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. The public record shows 348 publications with 6,200 citations (h-index 37), centered on Colorectal Cancer Treatments and Studies, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 49 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 49 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 116.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
Sponsor: ImStem Biotechnology
Industry payments
Updated 14 Oct 2026
49 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year20253 payments
- PFIZER INC.Program year20254 payments
- Exelixis Inc.Program year202513 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
68%Opioid Agonist43.4%Oxycodone Hcl80%Morphine Sulfate Er20%Part D<11 patientsBenzodiazepine16.6%Lorazepam100%Part D≥16 patients+ 1 more class in this area
Metabolism & gastrointestinal
18.3%Antidiarrheal18.3%Diphenoxylate-Atropine100%Part D≥14 patientsCancer & immunology
13.7%Kinase inhibitor13.7%Cabometyx50%Lenvima50%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
141 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).
ASCO Annual Meeting
ASCO2026Presenting author - A phase II study of enfortumab vedotin in patients with advanced or metastatic colorectal cancer or hepatocellular carcinoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits.
International journal of cancer
Article2026 - Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US.
The oncologist
Article2025 - Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.
JCO precision oncology
Article2025 - Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter].
Pragmatic and observational research
Comment2024
Most-cited works
by citation count (OpenAlex)- 01The Role of Angiogenesis in Hepatocellular Carcinoma548 citations2018
- 02
- 03Pulmonary Nontuberculous Mycobacterial Disease449 citations2008
- 04Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy346 citations2017
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- X / Twitter
x.com/MoffittNews/status/1796527140969587027
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn: "Richard Kim - Professor at Moffitt Cancer Center" (title corroborates primary source)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Miami School of Medicine (combined 6-year BS/MD program)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Internal Medicine Residency
University of Illinois at Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Fellowship in Hematology and Medical Oncology
Yale University Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Ad hoc editorial reviewer: Journal of Clinical Oncology
Annals of Oncology, Cancer, and Lancet Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- Former Clinical Assistant Professor
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
2010provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Associate Professor / Professor
University of South Florida (USF) Morsani College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Member
NCI Rectal/Anal Task Force
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Media & interviews
press, podcasts and appearances- OncLive video series (multiple appearances): commentary on HCC research at Moffitt
regorafenib in metastatic colorectal cancer, immunotherapy in colorectal cancer, and retifanlimab in anal cancer (SCAC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Contributing author/interviewee
GI Oncology Now
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gioncologynow.com ↗ - Featured speaker
VJOncology (video interviews on GI malignancies)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗ - Author/contributor
Journal of Oncology Navigation & Survivorship (AONN+)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jons-online.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Melissa Alsina, MD
H. Lee Moffitt Cancer Center & Research Institute
Alberto Chiappori, MD
H. Lee Moffitt Cancer Center & Research Institute
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH